US5534263A
(en)
*
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
CA2173818A1
(en)
*
|
1996-04-10 |
1997-10-11 |
Francois Chouinard |
Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose
|
US5804165A
(en)
*
|
1996-07-24 |
1998-09-08 |
Arnold; Michael J. |
Antiplaque oral composition
|
DE19640062B4
(en)
*
|
1996-09-28 |
2006-04-27 |
Lts Lohmann Therapie-Systeme Ag |
Oral preparation comprising in a matrix swellable in an aqueous medium at least one pharmaceutical active substance
|
IT1294760B1
(en)
*
|
1997-09-03 |
1999-04-12 |
Jagotec Ag |
PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL TABLETS ABLE TO RELEASE, ACCORDING TO PREDETERMINABLE SCHEMES, LITTLE ACTIVE INGREDIENTS
|
IN186245B
(en)
*
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
GB9724186D0
(en)
|
1997-11-14 |
1998-01-14 |
British Tech Group |
Low temperature coatings
|
HUP0100433A3
(en)
*
|
1997-12-22 |
2003-01-28 |
Schering Corp |
Orally administrable solid ribavirin dosage forms and process for producing them
|
PL344586A1
(en)
*
|
1998-06-05 |
2001-11-05 |
Warner Lambert Co |
Stabilization of compositions containing ace inhibitors using magnesium oxide
|
CN1531421A
(en)
*
|
1998-09-25 |
2004-09-22 |
�¶���˹ҩƷ��˾ |
Liquid pharaceutical for oral delivery
|
ATE424810T1
(en)
|
1998-12-11 |
2009-03-15 |
Nostrum Pharmaceuticals Inc |
A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
FR2797185B1
(en)
*
|
1999-08-06 |
2001-10-26 |
Galenix Dev |
FLOATING PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE AND A NON-ACTIVE PHASE
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
JP4565456B2
(en)
*
|
1999-11-02 |
2010-10-20 |
塩野義製薬株式会社 |
Color fixing method for colored granules
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
AR030557A1
(en)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
|
US6955821B2
(en)
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
EP1305021A4
(en)
*
|
2000-06-23 |
2009-09-23 |
Teva Pharma |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
DE10031043A1
(en)
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retarded preparations of quinolone antibiotics and process for their preparation
|
US20060099245A1
(en)
*
|
2000-08-01 |
2006-05-11 |
Manoj Kumar |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
TR200300731T2
(en)
|
2000-11-28 |
2004-08-23 |
Fmc Corporation |
Composition of edible PGA coating
|
JP2004513975A
(en)
*
|
2000-12-05 |
2004-05-13 |
マクグレゴール アレキサンダー |
Hydrostatic delivery system for controlled release of active substance
|
KR100685945B1
(en)
|
2000-12-29 |
2007-02-23 |
엘지.필립스 엘시디 주식회사 |
Liquid crystal display and manufacturing method of the same
|
US8268333B2
(en)
*
|
2001-04-24 |
2012-09-18 |
Lintec Corporation |
Orally administered agent and an orally administered agent/supporting substrate complex
|
DE10120092B4
(en)
*
|
2001-04-25 |
2008-03-20 |
Lts Lohmann Therapie-Systeme Ag |
Gastro-resistant device for the release of mucoadhesive active substance carriers and method for the production of the enteric device
|
IL159813A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
|
IL159812A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
WO2003041646A2
(en)
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
L-dopa ethyl ester salts and uses thereof
|
US6645526B2
(en)
*
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
WO2003042136A2
(en)
*
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
Process for the production of l-dopa ethyl ester
|
US20050123612A1
(en)
*
|
2001-12-21 |
2005-06-09 |
Cornelis Sobel |
Ribavirin granulate for producing coated tablets
|
KR20030056474A
(en)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
Manufacturing Method & Formulation of Controlled-release Carbidopa/Levodopa Tablets
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
KR20050083874A
(en)
*
|
2002-10-31 |
2005-08-26 |
알자 코포레이션 |
Dosage form providing ascending release of liquid formulation
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
JP2005132803A
(en)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
Solid pharmaceutical preparation staying in stomach
|
NZ547926A
(en)
|
2003-12-16 |
2009-10-30 |
Cnsbio Pty Ltd |
Methods and compositions for the treatment of neuropathic pain
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
WO2005084703A1
(en)
*
|
2004-03-09 |
2005-09-15 |
Nrl Pharma, Inc. |
Sustained-release composition for oral cavity
|
FR2874325B1
(en)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
|
CA2581002C
(en)
*
|
2004-10-15 |
2012-01-10 |
Supernus Pharmaceuticals, Inc. |
Less abusable pharmaceutical preparations
|
ES2516644T3
(en)
*
|
2004-11-19 |
2014-10-31 |
Glaxosmithkline Llc |
Pharmaceutical product
|
RU2401125C2
(en)
*
|
2004-12-27 |
2010-10-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Method of antidementia drug stabilisation
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
US20070003621A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
EP1912628A2
(en)
*
|
2005-06-29 |
2008-04-23 |
Panacea Biotec Ltd. |
Pharmaceutical sustained release compositions and processes thereof
|
DK1931346T3
(en)
*
|
2005-09-09 |
2012-10-22 |
Angelini Labopharm Llc |
Trazodone composition for once daily administration
|
NL2000281C2
(en)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Solid pharmaceutical compositions containing pregabalin.
|
US8187633B2
(en)
|
2005-11-03 |
2012-05-29 |
Sun Pharma Advanced Research Company Limited |
Controlled release coated tablets having prolonged gastric retention
|
EP1945188A2
(en)
*
|
2005-11-07 |
2008-07-23 |
Teva Pharmaceutical Industries Ltd. |
Levodopa compositions
|
US7674396B2
(en)
*
|
2005-11-08 |
2010-03-09 |
Plensat Llc |
Method and system for treatment of eating disorders
|
KR100752417B1
(en)
*
|
2006-02-14 |
2007-08-28 |
대원제약주식회사 |
A pharmaceutical composition containing mazindol having enhanced stability
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
JP2009535364A
(en)
*
|
2006-05-03 |
2009-10-01 |
シーエヌエスバイオ ピーティーワイ リミテッド |
Methods and compositions for the treatment of inflammatory pain
|
CA2654402A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Adel Penhasi |
Multiple unit pharmaceutical formulation
|
HUE032156T2
(en)
|
2006-06-19 |
2017-09-28 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical compositions
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
KR20090065519A
(en)
*
|
2006-08-30 |
2009-06-22 |
자고텍 아게 |
Controlled release solid oral dosage formulations comprising nisoldipine
|
JPWO2008041553A1
(en)
*
|
2006-09-26 |
2010-02-04 |
アステラス製薬株式会社 |
Tacrolimus sustained-release preparation
|
WO2008039193A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
EP2066303B1
(en)
*
|
2006-09-26 |
2016-05-04 |
Plensat, LLC |
System for treatment of eating disorders
|
EP1935411A1
(en)
|
2006-12-15 |
2008-06-25 |
Campina Nederland Holding B.V. |
Slow release excipient and its use
|
CA2673511A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
US20090011018A1
(en)
*
|
2006-12-28 |
2009-01-08 |
Astellas Pharma Inc., |
Sustained release formulation for tacrolimus
|
AT505225A1
(en)
|
2007-04-26 |
2008-11-15 |
Sanochemia Pharmazeutika Ag |
Tolperisone and their pharmaceutical acceptable salts and hydrates production for use as active substance in pharmaceutical formulation for drugs, for treatment and therapy of Alzheimer's disease, involves converting methylpropiophenone
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
WO2010005732A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Appian Labs, Llc |
Composition and method of preparation of release systems for constant (zero-order) release of active agents
|
MX340249B
(en)
|
2008-08-15 |
2016-07-01 |
Depomed Inc |
Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
|
AU2009301994B2
(en)
|
2008-10-08 |
2016-10-20 |
Bioplus Life Sciences Pvt. Ltd. |
Sustained release drug delivery system
|
US20100112054A1
(en)
*
|
2008-10-23 |
2010-05-06 |
Appian Labs, Llc |
Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
EP2210585A1
(en)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
SPRM pharmaceutical compositions methods of treatment using them
|
US20100249423A1
(en)
*
|
2009-03-09 |
2010-09-30 |
Sanochemia Pharmazeutika Ag |
Tolperisone controlled release tablet
|
WO2011078993A1
(en)
|
2009-12-21 |
2011-06-30 |
Aptapharma, Inc. |
Functionally-coated multilayer tablets
|
TR201802207T4
(en)
|
2010-03-29 |
2018-03-21 |
Astellas Pharma Inc |
Controlled Release Pharmaceutical Composition.
|
JP5459670B2
(en)
*
|
2010-05-07 |
2014-04-02 |
塩野義製薬株式会社 |
Color fixing agent for colored granules
|
US20130143867A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
AU2013213317B2
(en)
|
2012-01-23 |
2016-06-30 |
Sun Pharmaceutical Industries Limited |
In-situ multilayered tablet technology
|
CN105431144A
(en)
|
2013-06-05 |
2016-03-23 |
思康脑侒股份有限公司 |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
PL3054929T3
(en)
|
2013-10-07 |
2021-05-31 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
MX2016015891A
(en)
|
2014-06-02 |
2017-07-11 |
Teva Pharma |
Expandable gastroretentive dosage form.
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
EP3247384B1
(en)
|
2015-01-14 |
2023-10-04 |
The Regents of the University of Colorado, a body corporate |
In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
|
EP3288556A4
(en)
|
2015-04-29 |
2018-09-19 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
WO2017062997A1
(en)
|
2015-10-09 |
2017-04-13 |
Reckitt Benckiser Llc |
Pharmaceutical formulation
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US9820957B2
(en)
|
2016-03-24 |
2017-11-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of treating autoimmunity
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
ES2966736T3
(en)
|
2016-12-02 |
2024-04-24 |
Clexio Biosciences Ltd |
Gastric residence system
|
KR102039345B1
(en)
*
|
2017-02-01 |
2019-11-01 |
지엘팜텍주식회사 |
A high swellable sustained-release triple-layer tablet containing pregabalin
|
JP7433226B2
(en)
|
2017-12-01 |
2024-02-19 |
ウルトラジェニクス ファーマシューティカル インク. |
Creatine prodrugs, compositions and methods of use thereof
|
US11547839B2
(en)
|
2017-12-04 |
2023-01-10 |
Clexio Biosciences Ltd. |
Long acting gastric residence system
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019126218A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019126215A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
US11052060B2
(en)
|
2018-02-12 |
2021-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and methods for treating autoimmunity
|
US11013707B2
(en)
|
2018-03-23 |
2021-05-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Administration of oral methyldopa
|
AU2019269815A1
(en)
*
|
2018-05-15 |
2020-10-22 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Pharmaceutical composition comprising small molecule EGFR inhibitor and preparation method therefor
|
CN110214860A
(en)
*
|
2019-07-10 |
2019-09-10 |
聂刘明 |
A kind of feed for pet and its preparation process
|
AU2022320730A1
(en)
*
|
2021-07-30 |
2024-03-14 |
Evecxia Therapeutics, Inc. |
5-hydroxytryptophan gastroretentive dosage forms
|
US11779567B2
(en)
|
2021-10-14 |
2023-10-10 |
Evecxia Therapeutics, Inc. |
Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
WO2023214018A1
(en)
|
2022-05-06 |
2023-11-09 |
Galenix Innovations |
Gastro-retentive swellable sustained release composition
|